4235-43-2

Basic information

• Product Name: 4-ACETAMINO-5-CHLORO-2-ETHOXY METHYL BENZOATE
• Synonyms: 4-ACETAMINO-5-CHLORO-2-ETHOXY METHYL BENZOATE;METHYL 4-ACETAMIDO-5-CHLORO-2-ETHOXYBENZOATE;4-ACETYLAMINO-5-CHLORO-2-ETHOXY-BENZOIC ACID METHYL ESTER;Methyl 4-acetylamino-5-chloro-2-ethoxy-benzoate;Methyl 4-acetamido-5-chloro-2-ethoxybenzoate (Mosapride citrate)
• CAS NO: 4235-43-2
• Molecular Formula: C₁₂H₁₄ClNO₄
• Molecular Weight: 271.7
• Product Categories: Pharmaceutical Intermediates
• Mol File: 4235-43-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 448.529 °C at 760 mmHg
• Flash Point: 225.062 °C
• Appearance: /
• Density: 1.276 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.557
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly, Heated), Methanol (Slightly, Heated)
• CAS DataBase Reference: 4-ACETAMINO-5-CHLORO-2-ETHOXY METHYL BENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-ACETAMINO-5-CHLORO-2-ETHOXY METHYL BENZOATE(4235-43-2)
• EPA Substance Registry System: 4-ACETAMINO-5-CHLORO-2-ETHOXY METHYL BENZOATE(4235-43-2)

Safety Data

• Hazardous Substances Data: 4235-43-2(Hazardous Substances Data)

Usage

Uses

Methyl 4-acetamido-5-chloro-2-ethoxybenzoate (cas# 4235-43-2) could be a useful therapeutic agent for treating irritable bowel syndrome.

InChI:InChI=1/C12H14ClNO4/c1-4-18-11-6-10(14-7(2)15)9(13)5-8(11)12(16)17-3/h5-6H,4H2,1-3H3,(H,14,15)

Upstream product

• 4136-97-4 methyl 4-aminosalicylate 
• 65-49-6 4-Aminosalicylic acid 
• 4093-28-1 methyl 4-acetamido-2-hydroxybenzoate 

Downstream Products

• 131322-34-4 5-Chloro-2-ethoxy-N-[4-(4-fluoro-benzyl)-morpholin-2-ylmethyl]-4-formylamino-benzamide 
• 131322-30-0 4-{2-[(4-Amino-5-chloro-2-ethoxy-benzoylamino)-methyl]-morpholin-4-ylmethyl}-benzoic acid methyl ester 
• 112886-55-2 4-amino-5-chloro-N-[[4-(2-chlorobenzyl)-2-morpholinyl]methyl]-2-ethoxybenzamide 
• 112886-58-5 4-Amino-5-chloro-2-ethoxy-N-[4-(2-fluoro-benzyl)-morpholin-2-ylmethyl]-benzamide 
• 112885-41-3 mosapride 
• 112886-52-9 4-Amino-5-chloro-N-[4-(4-chloro-benzyl)-morpholin-2-ylmethyl]-2-ethoxy-benzamide 
• 131322-26-4 5-chloro-2-ethoxy-4-(fromylamino)benzoic acid 
• 131322-25-3 methyl 5-chloro-2-ethoxy-4-(formylamino)benzoate 
• 112914-03-1 methyl 4-amino-5-chloro-2-ethoxybenzoate 
• 183005-78-9 4-Acetylamino-5-chloro-2-ethoxy-3-nitro-benzoic acid methyl ester 
• 112914-09-7 4-(acetylamino)-5-chloro-2-ethoxybenzoic acid 
• 108282-38-8 4-amino-5-chloro-2-ethoxybenzoic acid 

Relevant articles and documents

Synthesis and biological evaluation of berberine derivatives as IBS modulator

Irritable bowel syndrome is the most common functional gastrointestinal disorder characterized by chronic abdominal pain or discomfort in association with a change in bowel habit. 5-HT receptor modulators have been developed as IBS therapeutic agents and proved to be effective in the treatment of the disease. In this letter, 12 berberine derivatives were designed and synthesized as 5-HT receptor modulators. Preliminary biological tests suggested that the new compounds exhibited promising activity for IBS therapy.

Novel benzamides as selective and potent gastrokinetic agents. 2.1 Synthesis and structure-activity relationships of 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl]methyl] benzamide citrate (AS-4370) and related compounds

The title compounds (19-55) with a 4-substituted 2-(aminomethyl)morpholine group were prepared and evaluated for the gastrokinetic activity by determining their effect on gastric emptying of phenol red semisolid meal in rats. Introduction of chloro, fluoro, and trifluoromethyl groups to the benzyl group of the parent compounds 1a and 1b enhanced the activity. Among compounds tested, 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl] methyl]benzamide (23b) showed the most potent gastric emptying activity (effects on phenol red semisolid meal in rats and mice, and on resin pellets solid meal in rats). The gastrokinetic activity of 23b citrate (AS-4370) compared very favorably with that of cisapride and was higher than that of metoclopramide. In contrast to metoclopramide and cisapride, AS-4370 was free from dopamine D2 receptor antagonistic activity in both in vitro ([3H]spiperone binding) and in vivo (apomorphine-induced emesis in dogs) tests.